Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics Chief Financial Officer reports tax-related share withholding. On January 20, 2026, CFO Patrick Fabbio had 3,063 shares of common stock withheld by Protara Therapeutics to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 19, 2024. The shares were treated as a disposition at $5.60 per share, and Fabbio now directly holds 67,376 shares of Protara Therapeutics common stock after this administrative transaction.
Protara Therapeutics, Inc. officer Jacqueline Zummo reported a tax-related share withholding transaction. On January 20, 2026, 6,578 shares of Protara common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards granted to her in January 2023 and January 2024.
After this withholding, Zummo directly beneficially owned 122,283 shares of Protara common stock. The filing characterizes the event as an automatic share withholding for taxes rather than an open-market sale.
Protara Therapeutics VP and Controller Hannah Fry reported a routine share withholding related to equity compensation. On January 20, 2026, the company withheld 2,132 shares of common stock at a value of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards originally granted on January 19, 2023 and January 19, 2024. After this tax-related transaction, Fry beneficially owned 44,180 shares of Protara Therapeutics common stock in direct ownership.
Protara Therapeutics reported new equity awards for its Chief Commercial Officer, William Conkling. On January 16, 2026, he received 26,000 shares of common stock at no cost, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, as long as he remains with the company.
He was also granted stock options covering 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. For these options, 25% of the shares vest on the one-year anniversary of January 16, 2026, and the remaining 75% vest in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 76,000 common shares and 158,000 options.
Protara Therapeutics Chief Financial Officer Patrick Fabbio reported new equity awards in the company. On January 16, 2026, he received 28,000 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second and third anniversaries of January 16, 2026, as long as he remains in continuous service. After this grant, he directly beneficially owned 70,439 shares of common stock.
On the same date, he was also granted 175,000 stock options with an exercise price of $5.01 per share. For these options, 25% vest on the one-year anniversary of January 16, 2026, and the remaining portion vests in equal monthly installments over the following three years, also conditioned on continued service. Following this grant, he directly held 175,000 stock options in total.
Protara Therapeutics VP and Controller Hannah Fry reported new equity awards. On January 16, 2026, she received 9,500 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, contingent on her continued service.
Fry was also granted a stock option for 55,000 shares of common stock with an exercise price of $5.01 per share, expiring on January 15, 2036. According to the award terms, 25% of these option shares vest on the one-year anniversary of January 16, 2026, and the remainder vest in equal monthly installments over the following three years, subject to continued service. After the RSU grant, she beneficially owned 46,312 common shares directly, and 55,000 options.
Protara Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, Nicacio Leonardo Viana. On January 16, 2026, he received stock options for 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. These options vest with 25% of the shares on the one-year anniversary of January 16, 2026, and the remaining shares vest in monthly installments over the following three years, conditioned on continued service.
He also acquired 26,000 shares of common stock at a price of $0 pursuant to restricted stock unit awards. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, also subject to continued service. Following these awards, he beneficially owns 78,181 shares of common stock directly, in addition to the unexercised options.
Protara Therapeutics CEO and President Jesse Shefferman reported new equity awards. On January 16, 2026, he received 87,000 shares of common stock at a price of $0 pursuant to restricted stock unit (RSU) awards, bringing his directly held common shares to 1,046,886.
He was also granted stock options covering 524,000 shares of common stock at an exercise price of $5.01 per share, with 524,000 derivative securities held directly after the grant. The RSUs vest in three equal annual installments on the first, second, and third anniversaries of January 16, 2026, contingent on his continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in equal monthly installments over the next three years, also subject to continued service, and expire on January 15, 2036.
Protara Therapeutics reported an equity compensation grant to its Chief Scientific Operations Officer, Jacqueline Zummo. On January 16, 2026, she received 30,000 shares of common stock for $0, issued pursuant to restricted stock unit awards. Following this grant, she beneficially owned 128,861 common shares directly.
The filing also shows a grant of 180,000 stock options with a $5.01 exercise price, recorded at a $0 acquisition cost. The RSUs vest in three equal annual installments on the first, second and third anniversaries of January 16, 2026, contingent on continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in 1/48th monthly installments over the next three years, also conditioned on ongoing service.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 2,408,868 shares of Protara Therapeutics, Inc. common stock, representing 4.7% of the outstanding class as of 12/31/2025. BlackRock reports sole power to vote 2,380,664 of these shares and sole power to dispose of 2,408,868 shares, with no shared voting or dispositive power.
The holdings reflect securities owned or deemed owned by certain BlackRock business units, excluding other disaggregated units. The shares are held in the ordinary course of business, and BlackRock states they were not acquired to change or influence control of Protara. Various underlying persons have rights to dividends or sale proceeds, but no one person has more than 5% of Protara’s total outstanding common shares.